RPE65 gene therapy slows cone loss in Rpe65-deficient dogs.
about
Clinical development of gene therapy: results and lessons from recent successesLipid Nanoparticles for Ocular Gene DeliveryA large animal model for CNGB1 autosomal recessive retinitis pigmentosa.Differential targeting of feline photoreceptors by recombinant adeno-associated viral vectors: implications for preclinical gene therapy trials.Long-term effect of gene therapy on Leber's congenital amaurosis.Halting progressive neurodegeneration in advanced retinitis pigmentosaHuman retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvementInvestigation of SLA4A3 as a candidate gene for human retinal diseaseAdvances in Gene Therapy for Diseases of the Eye.Gene therapy approaches for the treatment of retinal disordersImmuno-histochemical analysis of rod and cone reaction to RPE65 deficiency in the inferior and superior canine retina.Stem cells for investigation and treatment of inherited retinal disease.Dog models for blinding inherited retinal dystrophiesApplication of lipid nanoparticles to ocular drug delivery.AAV-mediated Gene Therapy Halts Retinal Degeneration in PDE6β-deficient Dogs.Gene Therapy in a Large Animal Model of PDE6A-Retinitis Pigmentosa.Photoreceptor-targeted gene delivery using intravitreally administered AAV vectors in dogs.Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65.Reduced retinal transduction and enhanced transgene-directed immunogenicity with intravitreal delivery of rAAV following posterior vitrectomy in dogs.Patients and animal models of CNGβ1-deficient retinitis pigmentosa support gene augmentation approach.Severe Loss of Tritan Color Discrimination in RPE65 Associated Leber Congenital Amaurosis.
P2860
Q26743393-539CBE92-BA36-4640-86FB-E88F3A907D99Q26823895-55BD32C3-A0BC-449B-951F-5C02DBB1F1E4Q34973721-F74DE4D6-BC3E-4516-A1EA-B88A2E68E707Q35804801-0D653329-502B-45F6-9510-A22AEA05CF69Q35836291-4CC03274-98A8-4E7B-85AC-446C088C3152Q36106057-4CB543CF-230D-473D-8CB2-79C4C2C5CD98Q36598421-61BD8911-20CF-4251-B224-20800650CEC5Q36925839-0B3C53BF-B684-4AF0-9A13-D157B3AC9538Q37190609-FA46AF95-31FE-4433-A593-07ECD624080EQ37481357-F50B27DB-ED5B-4DD6-AB9F-CD36DDF42084Q37500297-EC7C28DD-8ACF-40F0-AE5B-0657A2760CC2Q38197508-2C79820D-5278-4A0C-A851-D36F637E7D0DQ38351811-E0C751B7-8D76-47DF-817E-63166526F3A5Q38862505-B40E1B74-15DF-4CEC-A2BF-9E8747BBBC5FQ38910623-5E68C842-0D91-4EED-80E6-3F7C18500BC9Q40135224-7A81E2C7-123B-475A-BB37-5D1C131ED67BQ40490423-5D51360E-65D1-49C4-8C22-70AE80F6F783Q40571621-9ED0E86E-8E9B-457D-93E5-CA68364D1C14Q40814049-DA202C49-6F34-4A7F-BA1D-D0B4914060B7Q45875394-F10674A4-579F-4936-B060-405C9DD2E8F4Q48538458-67B3D136-1439-4670-B4DC-66F317DCF586
P2860
RPE65 gene therapy slows cone loss in Rpe65-deficient dogs.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
RPE65 gene therapy slows cone loss in Rpe65-deficient dogs.
@en
RPE65 gene therapy slows cone loss in Rpe65-deficient dogs.
@nl
type
label
RPE65 gene therapy slows cone loss in Rpe65-deficient dogs.
@en
RPE65 gene therapy slows cone loss in Rpe65-deficient dogs.
@nl
prefLabel
RPE65 gene therapy slows cone loss in Rpe65-deficient dogs.
@en
RPE65 gene therapy slows cone loss in Rpe65-deficient dogs.
@nl
P2093
P2860
P356
P1433
P1476
RPE65 gene therapy slows cone loss in Rpe65-deficient dogs.
@en
P2093
A R Breuwer
J T Bartoe
M J Annear
S M Petersen-Jones
P2860
P2888
P304
P356
10.1038/GT.2012.63
P577
2012-09-06T00:00:00Z
P6179
1013445754